IRINA Antonijevic

Company: EveryONE Medicines, Inc

Job title: Chief Medical Officer

Seminars:

Reducing the Burden of In Vivo Studies for IND & MAA Submission by Optimizing In Vitro Studies to Streamline Oligonucleotide Development to the Clinic for Ultra Rare Disease 4:30 pm

Exploring the crucial minimum requirements for in vitro and in vivo studies needed for IND and MAA submission, where ultra rare disease patients might have limited treatment window Using AI, chemistry and scaffold of the oligonucleotide to lower risk for candidate toxicity Assessing dose-response, immune-response, immunogenicity and cell viability to get the most out of…Read more

day: Conference Day One